Chard Daniel R

MED Chairman & CEO Chard buys 17.7K shares at $10.11; stock down -35.9% from 52-week high amid -36.0% revenue decline and unprofitability

Chard Daniel R, Chairman & CEO of MEDIFAST INC, purchased 17,678 shares at $10.11 on 2026-03-20, boosting his holdings to 188,233 shares (+10.4% vs pre-transaction). The purchase occurs against a backdrop of material operational deterioration: the company posted -$2.3M net income for its most recent full fiscal year, annual revenue declined -36.0%, and the stock has fallen -35.9% from its 52-week high of $15.22. At his prior MED purchase on 2025-06-13, the stock subsequently delivered a +9.7% 30-day return and +6.0% 90-day return, demonstrating one instance of favorable timing at this ticker. However, his current buy at $10.11 is positioned 4% above the 52-week low of $9.53 and faces headwinds from ongoing unprofitability and significant revenue contraction that warrant investor scrutiny into whether fundamentals have stabilized.

Chairman Daniel Chard bought 381 MED shares at $13.13 amid -43.8% revenue decline and $-772.0K net loss.

Chard Daniel R purchased 381 shares for $5,002.53, a small incremental addition to his 149.7K share position. The purchase occurred at $13.13, roughly 2.7% below the current market price of $13.49, but the stock remains down -38.5% from its 52-week high of $21.93. The underlying business context is materially adverse: latest quarterly revenue stands at $115.7M against an annual revenue decline of -43.8% year-over-year, and the company posted a net loss of $-772.0K. The P/E of 71.00 reflects earnings pressure. This buy in a contracting business environment merits examination of whether public disclosures support the transaction rationale and whether further deterioration or turnaround signals are evident in subsequent filings.